Shenzhen Kangzhe Listed on the “Corporate Donation List in of 2022 Shenzhen Charitable Donation List”
2023-09-25

Shenzhen Kangzhe Listed on the “Corporate Donation List in of 2022 Shenzhen Charitable Donation List”

Shenzhen Kangzhe Listed in “Shenzhen Top 500 Enterprises”

Shenzhen Kangzhe Listed in “Shenzhen Top 500 Enterprises”

Gained the Exclusive License of Cidine, an Exclusive, Marketed Oral Gastrointestinal Prokinetic Agent in China
2023-09-06

Gained the Exclusive License of Cidine, an Exclusive, Marketed Oral Gastrointestinal Prokinetic Agent in China

Gained Exclusive License of an Anti-Ischemic Stroke Class 1 Innovative Drug
2023-08-24

Gained Exclusive License of an Anti-Ischemic Stroke Class 1 Innovative Drug

First Prescription of Ruxolitinib Cream for Vitiligo Announced Under Boao Super Hospital’s Early Access Program
2023-08-19

First Prescription of Ruxolitinib Cream for Vitiligo Announced Under Boao Super Hospital’s Early Access Program

Received MSCI-ESG “AA” rating again, leading the industry globally
2023-07-28

Received MSCI-ESG “AA” rating again, leading the industry globally

Included in the First “Sustainability Yearbook (China)” of S&P Global
2023-06-29

Included in the First “Sustainability Yearbook (China)” of S&P Global

The first “Diazepam Nasal Spray” Approved for Marketing in China
2023-06-13

The first “Diazepam Nasal Spray” Approved for Marketing in China

Obtained Exclusive License of a Regenerative Medical Aesthetic Product
2023-05-31

Obtained Exclusive License of a Regenerative Medical Aesthetic Product

An Innovative Drug ILUMETRI “Tildrakizumab Injection” Approved for Marketing in China
2023-05-30

An Innovative Drug ILUMETRI “Tildrakizumab Injection” Approved for Marketing in China

Included in the “Hang Seng Innovative Drug Index”
2023-05-17

Included in the “Hang Seng Innovative Drug Index”

Ophthalmic Tetravalent Bispecific Antibody Product Being Granted an Approval for Drug Clinical Trial
2023-05-05

Ophthalmic Tetravalent Bispecific Antibody Product Being Granted an Approval for Drug Clinical Trial